Anti-fibrinolytic Agents in Traumatic Haemorrhage A Large Scale Randomised Controlled Trial is Needed_Chinese Journal of Evidence-Based Medicine

Authors：

Tim Coats , Beverley Hunt

1. University of Leicester; 2228 Princess Road West; Leicester LE1 6TP; UK2. Guy’s and St Thomas’ NHS Foundation Trust, Trust Offices, St Thomas Street, Guy’s Hospital,London,SE1 9RT,UK3. CRASH-2 trial co-ordinating centre, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK;

Corresponding author：

Keywords：

Anti-fibrinolytic agents; Traumatic Haemorrhage; Randomised controlled trial

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： Tim Coats,Beverley Hunt,Ian Roberts,Haleema Shakur. Anti-fibrinolytic Agents in Traumatic Haemorrhage A Large Scale Randomised Controlled Trial is Needed. Chinese Journal of Evidence-Based Medicine, 2005, 05(3): 251-252. doi: Copy

1.	［1］Murray CJL, Lopez AD. Global health statistics: a compendium of incidence, prevalence and mortality estimates for over 200 conditions[M]. Boston: Harvard University Press, 1996.
2.	［2］Sauaia A, Moore FA, Moore E, Moser K, Brennan R, Read RA, Pons PT. Epidemiology of trauma deaths: a reassessment[J]. J Trauma,1995; 38(2): 185-193.
3.	［3］The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care. Hypotension[J]. J Neurotrauma, 2000; 17(6-7): 591-595.
4.	［4］Lawson JH, Murphy MP. Challenges for providing effective hemostasis in surgery and trauma[J]. Semin Hematol, 2004; 41(sppul): s55-s64.
5.	［5］Porte RJ, Leebeek FW. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery[J]. Drugs, 2002; 62(15): 2 193-2 211.
6.	［6］Henry DA, Moxey AJ, Carless PA, O’Connell D, McClelland B, Henderson KM, Sly K, Laupacis A, Fergusson D. Antifibrinolytic use for minimising perioperative allogeneic blood transfusion (Cochrane Review)[M/CD]. In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd.
7.	［7］Coats T, Roberts I, Shakur H. Antifibrinolytic drugs for acute traumatic injury. (Cochrane Review)[M/CD]. In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd.
8.	［8］Aylward GW, Dunlop IS, Little BC. Meta-analysis of systemic antifibrinolytics in traumatic hyphema[J]. Eye, 1994; 8(3): 440-442.
9.	［9］Kiwanuka N, Gray RH, Serwadda D, Li X, Sewankambo NK, Kigozi G, Lutalo T, Nalugoda F, Wawer MJ. The incidence of HIV-1 associated with injections and transfusions in a prospective cohort, Raki, Uganda[J]. AIDS, 2004; 18(2): 342-343.
10.	［10］Heymann SJ, Brewer TF. The problem of transfusion associated acquired immunodeficiency syndrome in Africa: a quantitative approach[J]. Am J Infection Control, 1992; 20(5): 256-262.
11.	［11］Goodnough LT, Shander A, Brecher ME. Transfusion medicine: looking to the future[J]. Lancet , 2003; 361(9 352): 161-169.
12.	［12］www.crash2.lshtm.ac.uk.

1. ［1］Murray CJL, Lopez AD. Global health statistics: a compendium of incidence, prevalence and mortality estimates for over 200 conditions[M]. Boston: Harvard University Press, 1996.
2. ［2］Sauaia A, Moore FA, Moore E, Moser K, Brennan R, Read RA, Pons PT. Epidemiology of trauma deaths: a reassessment[J]. J Trauma,1995; 38(2): 185-193.
3. ［3］The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care. Hypotension[J]. J Neurotrauma, 2000; 17(6-7): 591-595.
4. ［4］Lawson JH, Murphy MP. Challenges for providing effective hemostasis in surgery and trauma[J]. Semin Hematol, 2004; 41(sppul): s55-s64.
5. ［5］Porte RJ, Leebeek FW. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery[J]. Drugs, 2002; 62(15): 2 193-2 211.
6. ［6］Henry DA, Moxey AJ, Carless PA, O’Connell D, McClelland B, Henderson KM, Sly K, Laupacis A, Fergusson D. Antifibrinolytic use for minimising perioperative allogeneic blood transfusion (Cochrane Review)[M/CD]. In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd.
7. ［7］Coats T, Roberts I, Shakur H. Antifibrinolytic drugs for acute traumatic injury. (Cochrane Review)[M/CD]. In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd.
8. ［8］Aylward GW, Dunlop IS, Little BC. Meta-analysis of systemic antifibrinolytics in traumatic hyphema[J]. Eye, 1994; 8(3): 440-442.
9. ［9］Kiwanuka N, Gray RH, Serwadda D, Li X, Sewankambo NK, Kigozi G, Lutalo T, Nalugoda F, Wawer MJ. The incidence of HIV-1 associated with injections and transfusions in a prospective cohort, Raki, Uganda[J]. AIDS, 2004; 18(2): 342-343.
10. ［10］Heymann SJ, Brewer TF. The problem of transfusion associated acquired immunodeficiency syndrome in Africa: a quantitative approach[J]. Am J Infection Control, 1992; 20(5): 256-262.
11. ［11］Goodnough LT, Shander A, Brecher ME. Transfusion medicine: looking to the future[J]. Lancet , 2003; 361(9 352): 161-169.
12. ［12］www.crash2.lshtm.ac.uk.

Chinese Journal of Evidence-Based Medicine

Anti-fibrinolytic Agents in Traumatic Haemorrhage A Large Scale Randomised Controlled Trial is Needed

Abstract Full text Figures/Tables Video References Cited by

Format

Content